Business Description
Immunocore Holdings PLC
NAICS : 541714
SIC : 2836
ISIN : US45258D1054
Share Class Description:
IMCR: ADRTotal Employee Number:
524Description
Immunocore Holdings PLC is a commercial-stage biotechnology company based in the United Kingdom. It develops targeted immunotherapies using its ImmTAX platform, which engineers soluble T cell receptor bispecific molecules designed to redirect the immune system against diseased cells. Its lead product, KIMMTRAK (tebentafusp), is approved for the treatment of unresectable or metastatic uveal melanoma and is also being studied in other cancers. The company's pipeline includes brenetafusp and additional ImmTAX candidates in oncology, infectious disease, and autoimmune indications. Immunocore generates revenue primarily from sales of KIMMTRAK, supplemented by collaboration and licensing agreements with partners such as Genentech, GlaxoSmithKline, and AstraZeneca. It sells its products in the United States, Europe, and other international markets, and invests heavily in research and development to expand its clinical programs.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.02 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 1.04 | |||||
Debt-to-EBITDA | 32.04 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.7 | |||||
Beneish M-Score | -2.33 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 27.7 | |||||
3-Year EBITDA Growth Rate | 52 | |||||
3-Year EPS without NRI Growth Rate | 18.4 | |||||
3-Year FCF Growth Rate | 35.7 | |||||
3-Year Book Growth Rate | 2.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.51 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.69 | |||||
9-Day RSI | 31.79 | |||||
14-Day RSI | 36.36 | |||||
3-1 Month Momentum % | 28.95 | |||||
6-1 Month Momentum % | 23.3 | |||||
12-1 Month Momentum % | 13.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.47 | |||||
Quick Ratio | 4.44 | |||||
Cash Ratio | 3.74 | |||||
Days Inventory | 522.26 | |||||
Days Sales Outstanding | 67.11 | |||||
Days Payable | 1966.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 0.61 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 98.9 | |||||
Operating Margin % | -5.24 | |||||
Net Margin % | -4.2 | |||||
EBITDA Margin % | 3.15 | |||||
FCF Margin % | -9.63 | |||||
OCF Margin % | -8.19 | |||||
ROE % | -4.57 | |||||
ROA % | -1.66 | |||||
ROIC % | -26.31 | |||||
3-Year ROIIC % | 35.14 | |||||
ROC (Joel Greenblatt) % | 20.13 | |||||
ROCE % | 1.14 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 143.2 | |||||
Forward PE Ratio | 2930.87 | |||||
PE Ratio without NRI | 354.07 | |||||
PEG Ratio | 7.11 | |||||
PS Ratio | 3.76 | |||||
PB Ratio | 3.95 | |||||
Price-to-Tangible-Book | 3.95 | |||||
EV-to-EBIT | 128.11 | |||||
EV-to-EBITDA | 92.78 | |||||
EV-to-Forward-EBITDA | 18.56 | |||||
EV-to-Revenue | 2.82 | |||||
EV-to-Forward-Revenue | 2.04 | |||||
EV-to-FCF | -29.24 | |||||
Price-to-GF-Value | 0.7 | |||||
| Price-to-Net-Current-Asset-Value | 4.72 | |||||
| Price-to-Net-Cash | 9.18 | |||||
Earnings Yield (Greenblatt) % | 0.78 | |||||
FCF Yield % | -2.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMCR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunocore Holdings PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 430.008 | ||
| EPS (TTM) ($) | 0.225 | ||
| Beta | 0.7122 | ||
| 3-Year Sharpe Ratio | -0.21 | ||
| 3-Year Sortino Ratio | -0.3 | ||
| Volatility % | 34.42 | ||
| 14-Day RSI | 36.36 | ||
| 14-Day ATR ($) | 1.180578 | ||
| 20-Day SMA ($) | 34.85325 | ||
| 12-1 Month Momentum % | 13.13 | ||
| 52-Week Range ($) | 27.555 - 40.7147 | ||
| Shares Outstanding (Mil) | 51.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunocore Holdings PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunocore Holdings PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-25 08:00 | In 157 days | ||
| Annual report for 2026 | 2027-02-25 | In 156 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 156 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 45 days | ||
| Guidance call for 2026 | 2026-09-15 12:15 | 32.46 (-1.34%) | ||
| Morgan Stanley 24(th) Annual Global Healthcare Conference | 2026-09-14 14:35 | 32.60 (-3.24%) | ||
| Guidance call for 2026 | 2026-09-10 14:45 | 34.47 (-1.96%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | 33.29 (-0.15%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 33.29 (-0.15%) | ||
| General meeting for 2026 | 2026-05-27 13:00 | 29.41 (+0.50%) |
Show
Entries
Immunocore Holdings PLC Frequently Asked Questions
What is Immunocore Holdings PLC(IMCR)'s stock price today?
The current price of IMCR is $32.22. The 52 week high of IMCR is $40.71 and 52 week low is $27.56.
When is next earnings date of Immunocore Holdings PLC(IMCR)?
The next earnings date of Immunocore Holdings PLC(IMCR) is 2026-11-06 Est..
Does Immunocore Holdings PLC(IMCR) pay dividends? If so, how much?
Immunocore Holdings PLC(IMCR) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers